<DOC>
	<DOCNO>NCT02784236</DOCNO>
	<brief_summary>Prospective study 6 month evolution people type 1 diabetes insulin multidose ( MDI ) HbA1c &gt; 7 % . Patients evaluate clinical , metabolic psychological baseline 6 month , telematic visit 3 month . We analyze : glycemic control ( HbA1c ) , glycemic variability ( SD MAGE ) , depressive symptom ( BDI-II ) , anxiety ( STAI ) , treatment-related ( DDS ) distress , fear hypoglycemia ( FH-15 ) , adhesion treatment ( SCI-R ) , quality life ( DQOL ) treatment satisfaction ( DTSQ ) platform .</brief_summary>
	<brief_title>INTEGRATED IMPACT ASSESSMENT Telemedicine Program Care Patients With Diabetes Mellitus Type 1 Intensive Treatment With Multiple Daily Injections .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Patients DM1 plus 1 year evolution . Age ≥18 &lt; 65 year . HbA1c prior study inclusion &gt; 7 % . MDI intensive insulin therapy basalbolus regimen . Patients candidate telemonitoring . Approximately 50 % patient work phone tablet Android operating system active data rate use wireless solution ( bluetooth ) OnLine MenaDiab® telemedicine . The remain patient work USB cable solution telemedicine MenaDiab® OnLine . Patients give write informed consent . Treatment ISCI . Chronic kidney disease , liver disease , thyroid dysfunction ( hypothyroidism except properly treat control ) . Pregnant planning pregnancy . Diabetes mellitus type 2 . Severe psychological disorder . Lack cooperation ( informed consent ) . Patients participate clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>